CEO Statement to Shareholders
Rhea-AI Summary
OSR Holdings (OSRH) issued a CEO statement on May 12, 2026, confirming it will not pursue a reverse stock split to regain Nasdaq minimum bid compliance. Management plans to restore compliance through operational execution and milestones, not structural actions.
According to OSR Holdings, the company signed definitive agreements with BCM Europe AG for a global exclusive license of oncology asset VXM01, with up to $815 million in potential milestone payments. Subsidiary Woori IO continues its non-invasive glucose monitoring collaboration with Samsung Electronics and NDA-protected discussions with Sinopharm.
AI-generated analysis. Not financial advice.
Positive
- VXM01 global license with BCM Europe AG, up to $815 million milestones
- No reverse stock split, avoiding immediate structural share change for investors
- Focus on organic recovery to restore Nasdaq bid compliance via execution
- Woori IO development with Samsung collaboration and Sinopharm NDA discussions
Negative
- Nasdaq minimum bid compliance remains unresolved and timing is uncertain
- No structural options like a reverse split retained as a contingency tool
Key Figures
Market Reality Check
Peers on Argus
OSRH was down 0.47% with low volume, while only one momentum peer (PHGE) appeared, moving down and broader peers showing mixed moves. This points to stock-specific focus on governance and Nasdaq compliance messaging rather than a sector-wide biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 05 | Analyst flash report | Positive | -10.8% | Research note reaffirming bullish view after VXM01 license and financing structure. |
| Apr 30 | Conference presentation | Positive | +52.8% | Announcement of VXM01 licensing presentation and live Q&A at growth conference. |
| Apr 29 | VXM01 license deal | Positive | -38.2% | Definitive global license for VXM01 with large milestone potential and IP transfer. |
| Apr 09 | Capital structure move | Positive | +3.8% | Convertible note to retire warrant overhang and support Nasdaq bid compliance. |
| Mar 30 | Investor update | Positive | +13.8% | Emerging Growth Conference update on VXM01 and Woori IO glucose platform. |
News tied to major licensing or financing actions has produced volatile and sometimes opposite reactions, with positive-sounding deals occasionally followed by sharp declines.
Over the past months, OSRH has focused on strategic licensing and capital-structure moves. The VXM01 global license with BCM Europe (up to $815M in milestones) and related financing steps, plus a warrant clean-up via a premium-priced convertible note, marked key milestones. Market reactions have been mixed, including sharp drawdowns after seemingly positive VXM01 news. Today’s CEO statement emphasizing no reverse split and an “execution-only” path to Nasdaq compliance fits this pattern of governance and capital-market messaging alongside the oncology and glucose-monitoring platforms.
Market Pulse Summary
This announcement underscores OSRH’s refusal to use a reverse stock split and its intent to regain Nasdaq compliance through execution. Management highlights the VXM01 license, with up to $815 million in potential milestones, and Woori IO’s non-invasive glucose monitoring collaboration as key value drivers. Recent history shows volatile reactions to licensing and capital-structure actions, so investors may watch how consistently the company delivers on oncology milestones, Woori IO development, and upcoming proxy-related governance decisions.
Key Terms
reverse stock split financial
preliminary proxy statement regulatory
non-invasive glucose monitoring medical
AI-generated analysis. Not financial advice.
A Clear Commitment: No Reverse Stock Split
BELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S. Securities and Exchange Commission on May 11, 2026. Given the proximity of our Nasdaq minimum bid compliance deadline, we believe it is important to provide direct and unambiguous transparency regarding our strategy.
Notably, the PRE 14A did not include a proposal authorizing a reverse stock split.
This was a deliberate decision, and it reflects our firm conviction.
We will not pursue a reverse stock split.
Management has evaluated this path and rejected it. We believe reverse splits do not create shareholder value. They are structural maneuvers that leave business fundamentals unchanged. We intend to earn our Nasdaq minimum bid compliance back through organic execution, not financial engineering.
Committed to Organic Recovery Driven by Subsidiary Milestones
On April 29, 2026, OSR Holdings executed definitive agreements with BCM Europe AG for the global exclusive license of VXM01, representing up to
In parallel, Woori IO continues to advance its non-invasive glucose monitoring platform through its collaboration with Samsung Electronics, while also progressing discussions under NDA with Sinopharm.
These are the kinds of developments that build real, durable shareholder value. We intend to continue delivering on them.
Our Position Is Clear
Management is focused entirely on restoring shareholder value through operational execution and strategic milestone delivery. We believe this is the right path forward for our shareholders, for our business, and for the long-term credibility of OSR Holdings as a public company.
There will be no reverse split. We believe the market will come to reflect the fundamental value we are building.
Commitment to Nasdaq Compliance Through Execution
Management remains fully committed to restoring compliance with Nasdaq's minimum bid requirement through the continued delivery of meaningful corporate milestones and disciplined engagement with the investment community - not through structural actions that do not improve our business fundamentals.
While there can be no assurance regarding timing or outcomes, we remain fully engaged with our advisors and Nasdaq as we work toward restoring compliance on our own terms.
We appreciate the continued support of our shareholders and remain confident in the long-term opportunities ahead for OSR Holdings.
Sincerely,
Kuk Hyoun "Peter" Hwang
Chief Executive Officer
OSR Holdings, Inc.
About OSR Holdings, Inc.
OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.
Investor Contact
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nasdaq compliance, strategic transactions, commercialization initiatives, and future business developments. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Holdings undertakes no obligation to update these statements except as required by law.
SOURCE: OSR Holdings, Inc.
View the original press release on ACCESS Newswire